VVY Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.09 |
| 52 Week High | €9.93 |
| 52 Week Low | €0.41 |
| Beta | 1.99 |
| 11 Month Change | -12.76% |
| 3 Month Change | -4.14% |
| 1 Year Change | -73.20% |
| 33 Year Change | -88.84% |
| 5 Year Change | -59.51% |
| Change since IPO | -89.58% |
Recent News & Updates
Recent updates
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14
Shareholder Returns
| VVY | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | -0.7% | -6.9% | -1.3% |
| 1Y | -73.2% | 0.8% | 7.1% |
Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned 0.8% over the past year.
Return vs Market: VVY underperformed the Dutch Market which returned 7.1% over the past year.
Price Volatility
| VVY volatility | |
|---|---|
| VVY Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in NL Market | 7.3% |
| 10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: VVY's share price has been volatile over the past 3 months compared to the Dutch market.
Volatility Over Time: VVY's weekly volatility has decreased from 28% to 12% over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| VVY fundamental statistics | |
|---|---|
| Market cap | €53.44m |
| Earnings (TTM) | -€31.18m |
| Revenue (TTM) | n/a |
-15.0x
P/S Ratio-1.7x
P/E RatioIs VVY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVY income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €28.09m |
| Earnings | -€31.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 85.50% |
| Net Profit Margin | 861.46% |
| Debt/Equity Ratio | 0% |
How did VVY perform over the long term?
See historical performance and comparison